Afatinib (4) and ibrutinib (5) were approved by the FDA to its list in 2013, the former for the metastatic NSCLC of missing EGFR exon 19 or the alternative mutation of exon 21 or nonresistant rare EGFR mutations (L861Q, G719X, S768I), and the latter for mantle cell lymphoma, chronic lymphocytic leukemia, fahrenheit giant globinemia, small lymphocytic lymphoma (as monotherapy or combined with benendamostetin + rituximab), recurrent refractory borderline lymphoma, chronic graft antihost disease, and rare lymphoplasmic cell lymphoma (combined with rituximab). This evidence concerns the gene EGFR and non-small cell lung carcinoma.